146 related articles for article (PubMed ID: 38751701)
1. Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells.
Mulliqi E; Khelwatty S; Morgan A; Ashkan K; Modjtahedi H
World J Oncol; 2024 Jun; 15(3):492-505. PubMed ID: 38751701
[TBL] [Abstract][Full Text] [Related]
2. The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells.
Al-Janaby T; Nahi N; Seddon A; Bagwan I; Khelwatty S; Modjtahedi H
World J Oncol; 2024 Apr; 15(2):192-208. PubMed ID: 38545471
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
4. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
5. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
[TBL] [Abstract][Full Text] [Related]
6. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
11. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
13. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
14. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
16. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
18. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG.
Shimizu M; Shirakami Y; Moriwaki H
Int J Mol Sci; 2008 Jun; 9(6):1034-1049. PubMed ID: 19325845
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
